FDA Finds Ingredient's IND Past After Signing Off For Supplement Use
This article was originally published in The Rose Sheet
Executive Summary
Supplement industry stakeholders say FDA makes an unjustifiable regulatory move by stating that the widely used dietary supplement ingredient is noncompliant, while the finding compels the agency to reverse its earlier acceptance of NDI notifications for vinpocetine.
You may also be interested in...
Amarin's Omega-3 Fair Trade Complaint Reaches Regulatory Dead End
International Trade Commission won't investigate Amarin's complaint that some dietary supplements containing omega-3 formulations similar to icosapent ethyl in its Vascepa are actually drugs and should be blocked from import into US, likely discouraging others from this novel approach.
Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards
Amarin's recent fair trade complaint targetting purified EPA dietary supplements and formulations also raises broader questions about using synthetic dietary ingredients in consumer supplements and the extent to which a substance’s identification in an IND precludes subsequent use as a dietary ingredient.
Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards
Amarin's recent fair trade complaint targetting purified EPA dietary supplements and formulations also raises broader questions about using synthetic dietary ingredients in consumer supplements and the extent to which a substance’s identification in an IND precludes subsequent use as a dietary ingredient.